Danaher Co. (NYSE:DHR) Receives $282.12 Average Price Target from Brokerages

Danaher Co. (NYSE:DHR) has been assigned an average recommendation of “Moderate Buy” from the eighteen analysts that are currently covering the firm, Marketbeat.com reports. Six research analysts have rated the stock with a hold recommendation and twelve have issued a buy recommendation on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $282.12.

Several research firms have recently weighed in on DHR. Robert W. Baird lifted their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus boosted their price objective on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Finally, Leerink Partners raised their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th.

Insider Transactions at Danaher

In related news, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the sale, the senior vice president now owns 20,230 shares in the company, valued at $5,566,486.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of Danaher stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the completion of the sale, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 39,659 shares of company stock worth $11,042,433. 11.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Danaher

Institutional investors have recently bought and sold shares of the stock. Tsfg LLC boosted its stake in shares of Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. CarsonAllaria Wealth Management Ltd. bought a new stake in Danaher in the 2nd quarter worth $25,000. nVerses Capital LLC bought a new position in shares of Danaher during the second quarter valued at about $25,000. Redmont Wealth Advisors LLC purchased a new stake in shares of Danaher during the first quarter worth about $30,000. Finally, Richardson Financial Services Inc. bought a new stake in shares of Danaher in the fourth quarter worth about $42,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Danaher Stock Performance

NYSE:DHR opened at $272.26 on Tuesday. Danaher has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The business has a fifty day simple moving average of $270.82 and a two-hundred day simple moving average of $260.34. The company has a market capitalization of $201.66 billion, a P/E ratio of 46.15, a P/E/G ratio of 4.49 and a beta of 0.83.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.05 EPS. On average, analysts expect that Danaher will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.40%. Danaher’s payout ratio is 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.